Inventor · disambiguated record
Dario Campana
Also filed as: CAMPANA DARIO
38 granted patents·16 pending applications·1,126 citations·filing 2004–2025
98Inventor score
Files withNAT UNIV SINGAPORE29ST JUDE CHILDRENS RES HOSPITAL INC10ST JUDE CHILDREN'S RES HOSPITAL INC5ST JUDE CHILDRENS RES HOSPITAL5CAMPANA DARIO3
Top patents by PatentIndex Score
54 records- 0198US9834590B2Chimeric receptors with 4-1BB stimulatory signaling domainST JUDE CHILDREN'S RES HOSPITAL INC·Filed 2015·Granted Dec 5, 2017·62 cites·16 claims
- 0298US9605049B2Chimeric receptors with 4-1BB stimulatory signaling domainST JUDE CHILDREN'S RES HOSPITAL INC·Filed 2014·Granted Mar 28, 2017·49 cites·16 claims
- 0398US8026097B2Expansion of NK cells and therapeutic uses thereofST JUDE CHILDRENS RES HOSPITAL·Filed 2008·Granted Sep 27, 2011·96 cites·3 claims
- 0498US7435596B2Modified cell line and method for expansion of NK cellST JUDE CHILDRENS RES HOSPITAL·Filed 2005·Granted Oct 14, 2008·158 cites·3 claims
- 0597US11873512B2Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious diseaseST JUDE CHILDRENS RES HOSPITAL INC·Filed 2020·Granted Jan 16, 2024·6 cites·19 claims
- 0697US11679132B2Methods for enhancing efficacy of therapeutic immune cellsNAT UNIV SINGAPORE·Filed 2022·Granted Jun 20, 2023·5 cites·12 claims
- 0797US10836999B2Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious diseaseST JUDE CHILDRENS RES HOSPITAL INC·Filed 2017·Granted Nov 17, 2020·13 cites·20 claims
- 0897US9856322B2Chimeric receptors with 4-1BB stimulatory signaling domainST JUDE CHILDREN'S RES HOSPITAL INC·Filed 2014·Granted Jan 2, 2018·62 cites·10 claims
- 0997US9511092B2Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious diseaseST JUDE CHILDREN'S RES HOSPITAL INC·Filed 2014·Granted Dec 6, 2016·36 cites·22 claims
- 1097US8399645B2Chimeric receptors with 4-1BB stimulatory signaling domainCAMPANA DARIO·Filed 2012·Granted Mar 19, 2013·469 cites·22 claims
- 1196US10829737B2Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious diseaseST JUDE CHILDRENS RES HOSPITAL INC·Filed 2017·Granted Nov 10, 2020·9 cites·24 claims
- 1296US10801012B2Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious diseaseST JUDE CHILDRENS RES HOSPITAL INC·Filed 2017·Granted Oct 13, 2020·9 cites·21 claims
- 1396US10774309B2Natural killer cell immunotherapy for treating cancerST JUDE CHILDRENS RES HOSPITAL INC·Filed 2017·Granted Sep 15, 2020·9 cites·11 claims
- 1496US10538739B2Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious diseaseST JUDE CHILDRENS RES HOSPITAL INC·Filed 2016·Granted Jan 21, 2020·9 cites·18 claims
- 1595US11673937B2Methods for expanding immune cellsST JUDE CHILDRENS RES HOSPITAL INC·Filed 2017·Granted Jun 13, 2023·7 cites·15 claims
- 1695US11560548B2Immune cells expressing membrane-bound interleukin 15 (mbIL15) and uses thereofNAT UNIV SINGAPORE·Filed 2020·Granted Jan 24, 2023·8 cites·18 claims
- 1795US10774311B2Natural killer cells modified to express membrane-bound interleukin 15 and uses thereofNAT UNIV SINGAPORE·Filed 2019·Granted Sep 15, 2020·14 cites·9 claims
- 1894US11945865B2Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignanciesNAT UNIV SINGAPORE·Filed 2022·Granted Apr 2, 2024·3 cites·15 claims
- 1994US10765699B2Methods for enhancing efficacy of therapeutic immune cellsNAT UNIV SINGAPORE·Filed 2016·Granted Sep 8, 2020·8 cites·12 claims
- 2094US10550183B2Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignanciesNAT UNIV SINGAPORE·Filed 2017·Granted Feb 4, 2020·11 cites·6 claims
- 2194US10428305B2Modified natural killer cells that express IL15 and uses thereofNAT UNIV SINGAPORE·Filed 2015·Granted Oct 1, 2019·28 cites·15 claims
- 2293US12264335B2Natural killer cells expressing membrane-bound interleukin 15 (mbIL15) and uses thereofNAT UNIV SINGAPORE·Filed 2022·Granted Apr 1, 2025·1 cites·20 claims
- 2393US11648269B2T cell receptor-deficient chimeric antigen receptor T-cells and methods of use thereofNAT UNIV SINGAPORE·Filed 2018·Granted May 16, 2023·6 cites·16 claims
- 2492US11896616B2Stimulatory cell lines for ex vivo expansion and activation of natural killer cellsNAT UNIV SINGAPORE·Filed 2018·Granted Feb 13, 2024·7 cites·9 claims
- 2592US11440958B2Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignanciesNAT UNIV SINGAPORE·Filed 2017·Granted Sep 13, 2022·8 cites·4 claims
- 2692US11365236B2Truncated NKG2D chimeric receptors and uses thereof in natural killer cell immunotherapyNAT UNIV SINGAPORE·Filed 2018·Granted Jun 21, 2022·13 cites·6 claims
- 2790US10144770B2Chimeric receptors and uses thereof in immune therapyNAT UNIV SINGAPORE·Filed 2014·Granted Dec 4, 2018·16 cites·31 claims
- 2887US2024092862A1Methods for expanding immune cellsST JUDE CHILDRENS RES HOSPITAL INC·Filed 2023·Application pending·0 cites
- 2987US2024191196A1Chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious diseaseST JUDE CHILDRENS RES HOSPITAL INC·Filed 2023·Application pending·0 cites
- 3086US2025354119A1Methods for enhancing efficacy of therapeutic immune cellsNAT UNIV SINGAPORE·Filed 2025·Application pending·0 cites
- 3181US12404492B2Methods for enhancing efficacy of therapeutic immune cellsNAT UNIV SINGAPORE·Filed 2022·Granted Sep 2, 2025·0 cites·21 claims
- 3281US2024182567A1Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignanciesNAT UNIV SINGAPORE·Filed 2024·Application pending·0 cites
- 3380US12479914B2T cell receptor-deficient chimeric antigen receptor T-cells and methods of use thereofNAT UNIV SINGAPORE·Filed 2023·Granted Nov 25, 2025·0 cites·19 claims
- 3479US12258381B2Activating chimeric receptors and uses thereof in natural killer cell immunotherapyNAT UNIV SINGAPORE·Filed 2019·Granted Mar 25, 2025·1 cites·17 claims
- 3575US2025320457A1Natural Killer Cells Expressing Membrane-Bound Interleukin 15 (mbIL15) and Uses ThereofNAT UNIV SINGAPORE·Filed 2025·Application pending·0 cites
- 3673US12404491B2Methods for enhancing efficacy of therapeutic immune cellsNAT UNIV SINGAPORE·Filed 2020·Granted Sep 2, 2025·0 cites·23 claims
- 3773US12351617B2Immune cells comprising truncated NKG2D chimeric receptorsNAT UNIV SINGAPORE·Filed 2022·Granted Jul 8, 2025·0 cites·8 claims
- 3872US2025388645A1Immune Cells Comprising Truncated NKG2D Chimeric ReceptorsNAT UNIV SINGAPORE·Filed 2025·Application pending·0 cites
- 3971US9777332B2Methods and compositions for identifying minimal residual disease in acute lymphoblastic leukemiaCAMPANA DARIO·Filed 2012·Granted Oct 3, 2017·3 cites·10 claims
- 4071US2025325587A1Blockade of cd3 expression and chimeric antigen receptors for immunotherapyMEDISIX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4167US2013216509A1Chimeric receptors with 4-1bb stimulatory signaling domainST JUDE CHILDRENS RES HOSPITAL·Filed 2013·Application pending·0 cites
- 4265US2017283482A1Chimeric Receptors with 4-1BB Stimulatory Signaling DomainST JUDE CHILDREN'S RES HOSPITAL INC·Filed 2017·Application pending·0 cites
- 4364US2013266551A1Chimeric receptors with 4-1bb stimulatory signaling domainST JUDE CHILDRENS RES HOSPITAL·Filed 2013·Application pending·0 cites
- 4462US2012015434A1Expansion of nk cells and therapeutic uses thereofCAMPANA DARIO·Filed 2011·Application pending·0 cites
- 4561US2018118845A1Chimeric Receptors with 4-1BB Stimulatory Signaling DomainST JUDE CHILDRENS RES HOSPITAL INC·Filed 2017·Application pending·0 cites
- 4655US2005113564A1Chimeric receptors with 4-1BB stimulatory signaling domainST JUDE CHILDRENS RES HOSPITAL·Filed 2004·Application pending·0 cites
- 4754US12129485B2Blockade of CD2 surface expression and expression of chimeric antigen receptors for immunotherapy of T-cell malignanciesNAT UNIV SINGAPORE·Filed 2019·Granted Oct 29, 2024·0 cites·10 claims
- 4853US2021214439A1Chimeric antigen receptors and gene editing of cd2 for immunotherapy of t-cell malignanciesNAT UNIV SINGAPORE·Filed 2019·Application pending·0 cites
- 4952US12486514B2Method to specifically stimulate survival and expansion of genetically-modified immune cellsNAT UNIV SINGAPORE·Filed 2019·Granted Dec 2, 2025·0 cites·12 claims
- 5052US2021054409A1Adhesion Receptor Constructs and Uses Thereof in Natural Killer Cell ImmunotherapyNAT UNIV SINGAPORE·Filed 2019·Application pending·0 cites
Showing the top 50 of 54 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Dario Campana files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →